CD274 and melanoma: Indeed, clinical studies identified that mCRC patients with higher PD-L1 expression in CRC cells might had a higher response rate than those patients with lower PD-L1 expression in CRC cells (42, 88), which was also supported by a meta-analysis of PD-L1 expression in patients with melanoma and lung and genitourinary cancers (89).